By Thania Benios Since its discovery in 1921, insulin has been called one of the few miracle drugs, having saved countless lives from an otherwise incurable disease. Yet 90 years later, treating and managing type 1 diabetes (T1D) is still a tricky business. Insulin, a hormone, is crucial to life. Without it, glucose cannot move […]
Consider a cluster of immature beta cells that are packaged in a device. The device is then implanted under the skin of a person with diabetes. Over time, the cells develop into functional islets. The end result: insulin production and blood glucose regulation. When JDRF announced its support of ViaCyte this month—an important step was […]
Could metformin, one of the most widely used drugs for type 2 diabetes, help to protect heart health and reduce complications in people with type 1 diabetes (T1D)? JDRF is funding a new trial to answer these questions. The REMOVAL study (REducing with MetfOrmin Vascular Adverse Lesions in T1D)—one of the largest trials targeted at […]
A hormone called GLP-1 has long been thought to have a positive impact on beta cell survival, and now scientists have started to uncover how it works. The new findings provide scientists with insights to improve the effects of currently available drugs that may prevent beta cell loss and promote beta cell survival in people with T1D or in those in the transplant setting.
Scientists have identified a pathway that allows beta cells to divide when they are young, but which turns off as the cells age. Finding drugs that could activate this pathway may provide a new way to make older beta cells divide again. This may be part of a strategy to maintain a quantity of beta
cells that is sufficient to restore insulin production in T1D.
An important protein involved in beta cell growth is snipped in T1D. Scientists have now identified the culprit—a molecular scissors called Bace2—and identified a chemical compound that inactivates it in mice. This inhibitor renews beta cell growth and could potentially lead to new strategies to promote beta cell regeneration to treat T1D. This is a key example of how science can advance when academic and industry scientists work together.
By Thania Benios In the 19th and early 20th centuries, diphtheria, measles, and mumps were frightening household names. Each year in the United States, these illnesses struck hundreds of thousands of people, and claimed up to tens of thousands of lives. Children were especially vulnerable to the bacteria and viruses that led to such staggering […]
People with type 1 diabetes may have a different makeup of gut flora—the microbes that live in the human digestive tract—compared to that found in people without the disease. By studying the collection of genes within this microbiome and assessing their functions, researchers hope to understand if, and how, an altered microbiome contributes to autoimmunity and the onset of type 1 diabetes.
In an effort to raise awareness for type 1 diabetes, one of the most costly chronic diseases in the world, JDRF co-hosted a two-day diabetes forum at the 2011 BIO International Convention, the first forum that BIO—the largest global event for the biotechnology industry—has ever dedicated to a specific disease. JDRF’s senior research staff actively […]
JDRF’s partnership with the Israel Science Foundation extends JDRF’s global research base and leverages JDRF research dollars to help people who are at risk for type 1 diabetes and improve the lives of those already living with the disease.